Navigation Links
Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
Date:2/1/2010

Therapure will build a dedicated production facility to support global markets for rare plasma proteins

Toronto, ON (PRWEB) February 1, 2010 -- Therapure Biopharma Inc. and LFB Biomedicaments, a wholly owned subsidiary of LFB S.A. a French biopharmaceutical company, today announced the signing of a toll manufacturing agreement under which Therapure will manufacture key plasma proteins to support an expansion by LFB into global plasma derived medicinal markets. Financial terms were not disclosed.

Under the terms of the agreement, Therapure will be responsible for the manufacture of two major plasma proteins and LFB will remain responsible for global regulatory approvals and marketing of these products. Therapure will retrofit its Health Canada licensed manufacturing facility to accommodate the installation of LFB proprietary technology and processes necessary to meets its manufacturing obligations.

The companies expect the facility to be completed in 2011. Qualification and validation process, including regulatory batches will be performed in 2012 in order to complete the regulatory approval process in the course of 2013.

The global market for plasma proteins is expected to grow at a rate of 6% over the next several years. These proteins extracted directly from human plasma include clotting factors that are crucial to patients with congenital or acquired bleeding disorders should be made widely available to these communities. Even though there are sometimes recombinant alternatives to a selection of these proteins, significant investments of time and money are required to bring new sources of supply to market. Therapure will produce these plasma-derived products using LFB’s existing technologies shortening in this manner the time required to bring the increased supply onto the market.

“We are proud to have been chosen by LFB as its contract manufacture
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
2. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
3. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
4. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
5. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
6. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
7. PDL BioPharma Announces Two $0.50 Dividends in 2010
8. Seven More Biopharmaceutical Research Companies Join PhRMA
9. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
10. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
11. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments 
(Date:3/28/2015)... 2015 Lately the student-athlete experience ... changes and proposals around the NCAA. In a March ... collegiate student-athletes across a spectrum of universities and sports ... challenges. The special panel consists of athletes who have ... from football, track and field, baseball, and volleyball. They ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 The ... method of sustainable health. After 18 years of research ... including professional UFC contenders, Dr. Jon Petrick is excited ... , Just some of the immediate benefits of this ... vitality, increased levels of strength of the immune system, ...
(Date:3/28/2015)... March 28, 2015 Purity Products®, ... supplements announces the release of their revolutionary new ... in two randomized, double-blind, placebo-controlled clinical studies to ... and hip size. MuffinStop™ is a combination of ... Garcinia mangostana, fused together to create one of ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership ... care provider for the 2015 and 2016 season. As the ... and an athletic trainer for the team throughout each season. ... against the Cleveland Gladiators at Amalie Arena; the game starts ... to us as it gives us the opportunity, to provide ...
Breaking Medicine News(10 mins):Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3
... Novavax Inc. (Nasdaq: NVAX) announced ... 12.5 million shares of Novavax,s common stock at $0.88 per share ... the new strategic alliance between Novavax and Cadila. Novavax intends to ... pay a portion of its 4.75% senior convertible notes due in ...
... that it reduces replication of the virus, , , WEDNESDAY, ... help people with HIV who don,t respond to standard ... the "gold standard" treatment for HIV is known as ... a number of drugs that reduce viral load by ...
... America (HFA) announces the publication of Living ... addition to HFA,s Living With Grief(R) book series. ... is a compilation of chapters by well-known experts in grief ... end-of-life decision making, shapes attitudes around the experience of terminal ...
... Albert Einstein College of Medicine of Yeshiva University have proposed ... brains of people with autism are structurally normal but dysregulated, ... , The central tenet of the theory, published in the ... autism is a developmental disorder caused by impaired regulation of ...
... schizoaffective disorder who received paliperidone extended release tablets ... in a broad range of schizoaffective symptoms, according ... 12th International Congress on Schizophrenia Research (ICOSR) in ... provide additional evidence for symptomatic improvement of schizoaffective ...
... April 1st, Professional Healthcare Resources celebrates 15 years of ... The company was started in 1994 by Eileen DeCesare ... an organization offering home health, hospice, and personal care ... The company has over 700 employees and eight branch ...
Cached Medicine News:Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2Health News:New HIV Drug May Help Those Resistant to Therapy 2Health News:Hospice Foundation of America Publishes New Book on Diversity and End-of-Life Care 2Health News:Einstein scientists propose new theory of autism 2Health News:Einstein scientists propose new theory of autism 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 7Health News:Professional Healthcare Resources Celebrates 15 Year Anniversary 2
(Date:3/27/2015)... Quebec , March 27, 2015  Valeant Pharmaceuticals ... today the closing of its previously announced registered offering ... (the "Offering"). Pursuant to the Offering, the ... $199.00 per share, for aggregate gross proceeds of approximately ... with the U.S. Securities and Exchange Commission a final ...
(Date:3/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... announced that they have entered into an ... proprietary sd-rxRNA® technology for use in developing ... the potential to result in novel, more ... could be a significant step toward personalized ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Calif., Aug. 12 Founder of the Dermatology Institute, Peter Rullan, ... Perfect™ treatments to his patients with the purchase of the ... excited to add this new service for our patients," Dr. Rullan ... wanted to find a system that not only met my patients, ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: www.pdl.com . ... logo are considered trademarks of PDL BioPharma, Inc. ... release contains forward-looking statements. Each of these forward-looking statements ... from those, express or implied, in these forward-looking statements. ...
Cached Medicine Technology:Chula Vista's Dr. Peter Rullan Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2PDL BioPharma Receives Letter from Genentech Relating to European Patents 2
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: